Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome

Area of Science:

• Endocrinology
• Bone Metabolism
• Neuroendocrinology

Background:

• Gut-derived serotonin influences bone formation, with its inhibition shown to increase bone mass in rodent models.
• Carcinoid neuroendocrine tumors provide a human model for studying the effects of serotonin excess due to high circulating serotonin levels.

Purpose of the Study:

• To investigate if carcinoid syndrome is associated with reduced bone formation markers, lower bone density, or impaired bone structure compared to healthy individuals.
• To evaluate the relationship between elevated serotonin levels and bone health parameters in patients with carcinoid syndrome.

Main Methods:

• A cross-sectional study involving 25 patients with carcinoid syndrome and 25 matched healthy controls.
• Measurements included circulating serotonin and 5-hydroxyindoleacetic acid (5HIAA), bone mineral density (lumbar spine, hip), bone structure (radius, tibia), and bone turnover markers (osteocalcin, PINP, CTX).

Main Results:

• Carcinoid patients exhibited significantly higher levels of serotonin and 5HIAA compared to controls.
• No significant differences were observed in bone density or bone structure between the two groups.
• Osteocalcin levels were higher in carcinoid patients (P = .02), while PINP and CTX levels did not differ.
• Positive correlations were found between 5HIAA and osteocalcin in patients, and between serotonin and bone turnover markers in controls.

Conclusions:

• Elevated circulating serotonin in carcinoid syndrome does not lead to clinically significant reductions in bone density or structural integrity.
• While osteocalcin was higher in carcinoid patients, overall bone formation markers and bone quality were not adversely affected by serotonin excess.
• The findings suggest a complex interplay between serotonin and bone metabolism that warrants further investigation.